CPT 0051U: UCompliDx LC–MS/MS Prescription Drug Detection

Headline: New PLA CPT code 0051U identifies a manufacturer-specific LC–MS/MS assay for prescription drug detection.

Lead: CPT code 0051U designates UCompliDx, a proprietary laboratory test from Elite Medical Laboratory Solutions LLC that uses liquid chromatography–tandem mass spectrometry (LC–MS/MS) on urine or blood to detect and quantify prescription drugs. The code formalizes reporting for a single-test proprietary assay and affects coverage, billing, and coding workflows for laboratories and payers nationwide.

What this code represents and why it matters: As a PLA CPT code, 0051U is tied to one unique laboratory assay rather than a generic test descriptor. Nationally, PLA codes like 0051U influence how labs bill for specialized diagnostics, how payers adjudicate claims for novel assays, and how clinicians order and interpret high-specificity drug testing.

Key payers covered: Analysis includes major national payers — Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare — to reflect likely coverage and billing interactions for this test.

What readers will learn: The publication summarizes the clinical purpose and laboratory setting for CPT code 0051U, outlines common billing considerations for PLA codes, and presents benchmarks and policy context relevant to coverage and claim processing. Data gaps and payer-specific policies are noted as available; where input data is missing, the report indicates "Data not available in the input."

Billing Code Overview

CPT code 0051U is a Proprietary Laboratory Analyses (PLA) code that applies to a single, manufacturer-specific diagnostic test. Report CPT code 0051U for UCompliDx from Elite Medical Laboratory Solutions LLC. The test uses liquid chromatography and tandem mass spectrometry (LC–MS/MS) of a urine or blood specimen to determine the presence or absence and the quantity of prescription drug(s) in a patient’s body.

Service type: Specialized laboratory testing using LC–MS/MS for prescription drug detection and quantification

Typical site of service: Independent clinical laboratory or reference laboratory performing specimen analysis on urine or blood samples

Clinical Context

A 42-year-old patient enrolled in an opioid use disorder treatment program is scheduled for targeted therapeutic drug monitoring. The clinician orders 0051U (UCompliDx) to perform LC–MS/MS on a urine specimen to identify and quantify prescribed opioid and non-opioid medications for adherence verification and to detect undisclosed substances. Specimen collection is observed or unobserved per clinic policy, labeled, and sent to the reference laboratory. The laboratory performs confirmatory testing using LC–MS/MS, generates a quantitative report of detected prescription drugs, and returns results to the ordering provider. Results inform care decisions such as medication reconciliation, treatment planning, and potential referral for substance use counseling. Typical site of service is an outpatient clinic, addiction treatment center, or clinical laboratory; specimens may be collected at the clinic, an ambulatory collection site, or at-home collection with proper chain-of-custody procedures when applicable.

Coding Specifications

Modifier	Description	When to Use
`00`	Modifier not used (placeholder)	Not applicable for billing; retained in list per input.
`11`

Taxonomy Code	Specialty	Notes
`1835P0001X`	Clinical Pathology	Laboratory directors and pathologists overseeing toxicology testing and quality assurance.
`207RP0501X`	Addiction Medicine	Clinicians ordering quantitative LC–MS/MS for monitoring patients in substance use treatment programs.
`363L00000X`	Laboratory Services	Clinical laboratory personnel and organizations performing specimen analysis using LC–MS/MS.
`208D00000X`	Family Medicine	Primary care physicians who order medication monitoring for chronic pain or substance use disorder management.
`207L00000X`	Psychiatry & Neurology	Psychiatrists providing medication management and monitoring for behavioral health patients.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`F11.20`	Opioid dependence, uncomplicated	Common indication for quantitative drug testing to verify opioid medication adherence and detect nonprescribed opioids.
`F11.10`	Opioid abuse, uncomplicated	Used for monitoring patients with opioid misuse history during treatment programs.
`Z79.891`	Long term (current) use of opiate analgesic	Documentation of chronic opioid therapy where monitoring with LC–MS/MS may be indicated.
`F11.21`	Opioid dependence, in remission	Monitoring to confirm abstinence or detect relapse in remission management.
`R78.89`	Other abnormal urine findings	Laboratory abnormality prompting specific confirmatory testing for substances.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81002`	Urinalysis, by dipstick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, specific gravity, etc., non-automated; reagent strip	Useful as a point-of-care screen before sending a specimen for confirmatory LC–MS/MS; primitive screen for sample validity markers.
`80307`	Drug test(s), presumptive, any number of drug classes; each procedure	May be used for initial immunoassay screening prior to confirmatory quantitative LC–MS/MS testing with `0051U`.
`80305`	Drug test(s), presumptive, any number of drug classes; presumptive drug class screen, single class	Represents single-class presumptive screens that can precede comprehensive PLA confirmatory testing.
`80104`	Drug assay, qualitative; immunoassay with chromatographic confirmation when performed, each procedure	Reflects workflows where qualitative immunoassay with confirmation occurs; LC–MS/MS PLA `0051U` provides high-specificity quantitation after confirmation.
`G0480`	Drug screen, definitive, any number of drug classes; e.g., GC/MS, LC/MS/MS	Alternative definitive drug testing HCPCS that may be used in similar clinical contexts when PLA codes are not applicable.

OpenPayer

Summary & Overview